Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.
about
Molecular signaling involving intrinsically disordered proteins in prostate cancerHydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actionsThe evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistanceTargeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.N-terminal truncations in sex steroid receptors and rapid steroid actions.Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.Re-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer - a thorough conformational and binding analysis for ROR-γ protein.Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
P2860
Q26747089-235E30B6-8E24-4A17-967C-C8340F90128DQ33947136-B2BAA554-A53E-4C3E-85E5-B8CDE256A330Q34249190-D4636FB0-156E-4074-BDF3-FFC381E90A0DQ34495028-884C0DE5-AB82-4F24-BBA8-9AC5893BE67BQ36508759-04756B33-1C1C-43F7-B49B-4B682630E55EQ37180541-579E6B80-0B22-4B30-870F-26C741CDBDC6Q38250639-46B63AF6-5580-4DCB-96A6-AC77779ED50FQ38265574-4613736F-8F88-4F71-A8D6-47896E07338FQ38410885-4C2E3C33-E3B0-4ED2-8EF2-BCF2E68B0A40Q38739244-A3EF1E72-52DE-420A-8B4F-5800F2265D25Q38883820-0B0EF479-193D-4272-B49A-DE8F7F546971Q47440133-2B49F2CC-7222-44F4-8DB2-CC10F6188DB0Q47602394-4BDFDF94-5C9F-476F-8569-C9D3A4639D11Q50226984-47D1BCAC-D9DD-4076-8D7D-DB5E5D337B7FQ51232936-D4ABE28E-635B-440F-92B5-AB05B77FFABAQ53126460-0B3F9B49-BE1F-4956-A37C-0DF9FD46233DQ55331819-EA147DC3-DC4A-4525-A2FB-9AA1F554F9EE
P2860
Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting alternative sites on ...... ion-resistant prostate cancer.
@en
type
label
Targeting alternative sites on ...... ion-resistant prostate cancer.
@en
prefLabel
Targeting alternative sites on ...... ion-resistant prostate cancer.
@en
P2093
P2860
P356
P1476
Targeting alternative sites on ...... ion-resistant prostate cancer.
@en
P2093
Artem Cherkasov
Kush Dalal
Nada Lallous
Paul S Rennie
P2860
P304
12496-12519
P356
10.3390/IJMS140612496
P407
P5008
P577
2013-06-14T00:00:00Z